Sep JW Therapeutics (Suzhou) Co., Ltd. founded Nov Started world-leading commercial scale cell therapy manufacturing project Dec JW Therapeutics R&D center opened 2019 Feb Recognized as a “Foreign-invested R&D center” by Shanghai Municipal People’s Government Dec Completed cell therapy commercia...
JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a...
If you have any questions about the Platform and related Services, please contact us in the following ways and give a full description, and We will try our best to solve them. Company Name: JW Therapeutics (Shanghai) Co., Ltd. Contact Phone: +86 21 50783699...
Shanghai, China, August 20, 2021- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy, today announced that it has entered into a strategic partnership with MediTrust Health. Leveraging the respective business...
SHANGHAI, CHINA,January2, 2024-JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development ...
JW (Cayman) Therapeutics Co. Ltd * (Incorporated in the Cayman Islands with limited liability) Stock Code: 2126 Annual Report * Contents 2 Corporate Information 4 Chairman's Statement 7 Financial Highlights 11 Business Highlights 14 Management Discussion and Analysis 41 Directors and Senior Management...
JW (Cayman) Therapeutics Co. Ltd 藥明巨諾(開曼)有限公司* (於開曼群島註冊成立的有限公司) (股份代號:2126) 自願公告 業務更新 國家藥品監督管理局接受倍諾達®治 療 復發或難治性細胞淋巴瘤患者的補充生物製品許可申請 JW (Cayman) Therapeutics Co. Ltd(藥明巨諾(開曼)有限公司*)(「本公司」 或「藥明...
James Li, Co-founder, Chairman and CEO of JW Therapeutics, said, “Autoimmune diseases are a critical part of JW Therapeutics’ strategy. We are committed to maximizing the clinical value of relma-cel, and look ...
Shanghai, China, March 26, 2020– JW Therapeutics (stock code: 2126.HK), a leading cellular immunotherapy company, today announced 2020 annual results. Business Highlights 2020 was a transformative year in our Company’s history. In June 2020, we submitted a new drug application (NDA) to the...
简介:JW (Cayman) Therapeutics Co. Ltd,成立于2020年,位于香港特别行政区。 展开 项目品牌:JW Therapeutics 融资历程0竞品数量21 企业全景 瞬息掌握企业关系 天眼图谱 登记信息 发生变更时通知我 自身风险 0条该公司暂无自身风险信息 周边风险 0条该公司暂无周边风险信息 ...